XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Assets and Liabilities - Assets and Liabilities (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
property
shares
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Mar. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Losses on equity securities, net $ (8,553) $ (8,339)    
Corporate Joint Venture | Seaport Innovation LLC        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Equity method investment ownership percentage 20.00%   20.00% 55.00%
Holding period 10 years      
Corporate Joint Venture | Seaport Innovation LLC | Measurement Input, Discount Rate        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Measurement input 0.0558      
Corporate Joint Venture | Seaport Innovation LLC | Measurement Input, Market Capitalization Rate        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Measurement input 0.0525      
Corporate Joint Venture | Medical Office and Life Science Properties        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Equity method investment ownership percentage 20.00%      
Holding period 10 years      
Number Of owned properties | property 10      
Corporate Joint Venture | Medical Office and Life Science Properties | Measurement Input, Discount Rate | Minimum        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Measurement input 0.0567      
Corporate Joint Venture | Medical Office and Life Science Properties | Measurement Input, Discount Rate | Maximum        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Measurement input 0.0893      
Corporate Joint Venture | Medical Office and Life Science Properties | Measurement Input, Market Capitalization Rate | Minimum        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Measurement input 0.0475      
Corporate Joint Venture | Medical Office and Life Science Properties | Measurement Input, Market Capitalization Rate | Maximum        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Measurement input 0.0600      
Recurring | Carrying Amount | AlerisLife Inc        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investments in affiliates, fair value $ 22,987      
Recurring | Level 1 | Carrying Amount | AlerisLife Inc        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investments in affiliates, fair value $ 22,987   $ 31,540  
Equity securities investment (in shares) | shares 10,691,658      
Recurring | Level 1 | Estimated Fair Value | AlerisLife Inc        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investments in affiliates, fair value $ 22,987   31,540  
Recurring | Level 3 | Joint Venture | Carrying Amount | Life Science Property        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investments in affiliates, fair value     215,127  
Recurring | Level 3 | Joint Venture | Carrying Amount | Medical Office and Life Science Properties        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investments in affiliates, fair value     0  
Recurring | Level 3 | Joint Venture | Estimated Fair Value | Life Science Property        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investments in affiliates, fair value 216,416   215,127  
Recurring | Level 3 | Joint Venture | Estimated Fair Value | Medical Office and Life Science Properties        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investments in affiliates, fair value $ 50,325   $ 0